Phase 3 N=24 Arimoclomol in Sporadic Inclusion Body Myositis
Inclusion Body Myositis
Primary: Count of Adverse Events Reported — 109; 52 adverse events reported
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=17 Belimumab in Idiopathic Inflammatory Myositis
Myositis
Primary: Response Rate During Randomized Phase — 3; 1; 5; 2 Participants — p=0.60
Phase 3 N=25 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus
Interstitial Pneumonitis · Polymyositis · Dermatomyositis
Primary: Overall Survival — 88.0 percentage of participants
Phase 2 N=75 A Study In Adults With Moderate To Severe Dermatomyositis
Dermatomyositis
Primary: Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) — -3.44…
Phase 2 N=36 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Dermatomyositis · Polymyositis
Primary: Compare the Average Total Improvement Scores at Visits 2 Through 7 During the 6-month Treatment Period Between the Treatment and Placebo Arms — 26.4; 29.3 score on a…
Phase 3 N=95 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
Dermatomyositis
Primary: Measure the Number of Patients Who Had an Increase of ≥20 Points on the Total Improvement Score (TIS) — 21; 37 Participants
Phase 2 N=12 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Dermatomyositis · Polymyositis
Primary: Specific Aim 1: Number of Subjects Meeting IMACS Preliminary Definition of Improvement (DOI). — 7 Participants
Phase 3 N=148 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
Polymyositis · Dermatomyositis · Autoimmune Necrotizing Myopathy
Primary: Number of Participants Achieving International Myositis Assessment and Clinical Studies Definition of Improvement (IMACS DOI) at Week 24 Without Rescue — 42; 31…
N/A N=99 Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise
Stroke · Inflammation
Primary: Cardiovascular Fitness (VO2 Peak) — 15.9; 16.6; 21.3; 17.5 ml/kg/min — p=0.001
Phase 2 N=152 Study of Arimoclomol in Inclusion Body Myositis (IBM)
Inclusion Body Myositis
Primary: Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score — -3.26; -2.26 score on a scale — p=0.1146
Phase 2 N=30 Trial of IMO-8400 in Adult Patients With Dermatomyositis
Dermatomyositis
Primary: To Assess the Safety and Tolerability of IMO-8400 in Adult Subjects With DM — 6; 4; 2; 4 participants
N/A N=22 Regulation of Muscle Protein Phenotype in Humans With Obesity
Obesity
Primary: Whole-Muscle Protein Synthesis — 0.004; 0.015 %/hr
Phase 2 N=20 Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease
Myositis · Interstitial Lung Disease
Primary: % Predicted Forced Vital Capacity (FVC) Absolute Change — -1.70; -2.05 % predicted FVC — p=<0.05
Phase 2 N=63 Antioxidant Therapy in RYR1-Related Congenital Myopathy
Neuromuscular Disease
Primary: Urine 15-F2t Isoprostane Concentration — 2.7; 2.6 ng/mg Cr — p=0.88
Phase 2 N=200 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
Myositis · Dermatomyositis · Polymyositis
Primary: Comparison Between the Time to Improvement Between the Two Groups of IIM (Idiopathic Inflammatory Myopathy) Patients — 20.2; 20.0 Weeks — p==0.74
Phase 2 N=25 A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
Polymyositis · Dermatomyositis
Primary: Mean Change in the Total Improvement Score (TIS) From Start to End of Zetomipzomib (KZR-616) Treatment Period — 25.5; 25.0; 33.1; 33.5 score on a scale
Phase 2 N=17 Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
Myotonic Dystrophy
Primary: The Number of Study Participants Who Safely Tolerated Somatokine — 6; 9 participants
Phase 2 N=8 Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis
Dermatomyositis, Adult Type
Primary: The Primary Endpoint Analysis Would be Overall Response Rate Measured by the Number of Participants Experiencing at Least 4 Points Decrease in CDASI Activity Score at 3…
N/A N=40 Ultrasound in Muscle Biopsy
Myopathy · Myositis · Muscular Dystrophy
Primary: Amount of Tissue Obtained — 0.29; 0.28 grams
Phase 3 N=10 Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Sporadic Inclusion Body Myositis (sIBM)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 0; 2; 10 Participants
Phase 2 N=103 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis
Systemic Lupus Erythematosus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 101; 27 participants
Phase 3 N=14 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
Dermatomyositis · Idiopathic Inflammatory Myopathies
Primary: Change in Calcinosis Activity Visual Analogue Scale Score — -3.45 Units on a scale
Phase 2 N=59 Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia
Myotonia · Non-Dystrophic Myotonia
Primary: Patient-reported Stiffness on the IVR — 2.53; 4.21; 1.60; 5.27 units on a scale — p=<0.001
N/A N=42 Quantifying Myofascial Dysfunction in Post-Stroke Pain
Myofascial Dysfunction
Primary: T1 Rho MRI Relaxation Time of Shoulder External Rotator (Milliseconds) — 29.09; 27.15 milliseconds
Phase 1 N=16 A Pilot Study of Etanercept in Dermatomyositis
Dermatomyositis
Primary: Occurrence of at Least One Adverse Event — 1; 1; 5; 1 participants
Phase 1 N=7 S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)
RYR-1 Myopathy
Primary: Number of Participants Experiencing Adverse Events When Treated With S48168 (ARM210) — 0; 0; 0; 0 Participants
Phase 3 N=300 The Effect of Pretreatment With Roc on Succinylcholine Myalgias
Myalgia
Primary: Myalgias Perceived at 3 Hours — 81; 83; 83; 15 Participants
Phase 2 N=18 Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
Polymyositis · Dermatomyositis
Primary: Mean Total Improvement Score (TIS) at OLE Week 48 — 36.4 score on a scale
Phase 3 N=31 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM
Polymyositis · Dermatomyositis
Primary: The Primary Endpoint is the Total Dose of Glucocorticoids Administered Between Baseline and the End of Treatment. — 124; 135 mg/kg
Phase 3 N=251 Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
Sporadic Inclusion Body Myositis
Primary: Change From Baseline in 6 Minute Walking Distance (6MWD) Test at Week 52 — 8.63; 9.63; -10.27; -8.96 meters — p=0.2210